leadf
logo-loader
RNS
viewAstraZeneca

AstraZeneca PLC - Director Declaration

RNS Number : 1169T
AstraZeneca PLC
16 July 2020
 

16 July 2020 07:00 BST

 

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed as an independent Non-Executive Director of CSL Limited (ASX:CSL; USOTC:CSLLY), to be effective from 19 August 2020.

 

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNXELFFBDLZBBX

Quick facts: AstraZeneca

Price: 8118

Market: LSE
Market Cap: £106.53 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read